|Huntington's disease: from molecular pathogenesis to clinical treatment|
CA Ross, SJ Tabrizi
The Lancet Neurology 10 (1), 83-98, 2011
|Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data|
SJ Tabrizi, DR Langbehn, BR Leavitt, RAC Roos, A Durr, D Craufurd, ...
The Lancet Neurology 8 (9), 791-801, 2009
GP Bates, R Dorsey, JF Gusella, MR Hayden, C Kay, BR Leavitt, M Nance, ...
Nature reviews Disease primers 1 (1), 1-21, 2015
|Huntington disease: natural history, biomarkers and prospects for therapeutics|
CA Ross, EH Aylward, EJ Wild, DR Langbehn, JD Long, JH Warner, ...
Nature Reviews Neurology 10 (4), 204-216, 2014
|Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data|
SJ Tabrizi, RI Scahill, G Owen, A Durr, BR Leavitt, RA Roos, B Borowsky, ...
The Lancet Neurology 12 (7), 637-649, 2013
|PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death|
S Gandhi, A Wood-Kaczmar, Z Yao, H Plun-Favreau, E Deas, K Klupsch, ...
Molecular cell 33 (5), 627-638, 2009
|A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease|
M Björkqvist, EJ Wild, J Thiele, A Silvestroni, R Andre, N Lahiri, ...
The Journal of experimental medicine 205 (8), 1869-1877, 2008
|Proteome-based plasma biomarkers for Alzheimer's disease|
A Hye, S Lynham, M Thambisetty, M Causevic, J Campbell, HL Byers, ...
Brain 129 (11), 3042-3050, 2006
|Biochemical abnormalities and excitotoxicity in Huntington's disease brain|
SJ Tabrizi, MWJ Cleeter, J Xuereb, JW Taanman, JM Cooper, ...
Annals of Neurology: Official Journal of the American Neurological …, 1999
|Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis|
SJ Tabrizi, RI Scahill, A Durr, RAC Roos, BR Leavitt, R Jones, ...
The Lancet Neurology 10 (1), 31-42, 2011
|Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data|
SJ Tabrizi, R Reilmann, RAC Roos, A Durr, B Leavitt, G Owen, R Jones, ...
The Lancet Neurology 11 (1), 42-53, 2012
|Microglial activation in presymptomatic Huntington's disease gene carriers|
YF Tai, N Pavese, A Gerhard, SJ Tabrizi, RA Barker, DJ Brooks, P Piccini
Brain 130 (7), 1759-1766, 2007
|Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse|
SJ Tabrizi, J Workman, PE Hart, L Mangiarini, A Mahal, G Bates, ...
Annals of neurology 47 (1), 80-86, 2000
|PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons|
A Wood-Kaczmar, S Gandhi, Z Yao, ASY Abramov, EA Miljan, G Keen, ...
PloS one 3 (6), e2455, 2008
|Disease-associated prion protein oligomers inhibit the 26S proteasome|
M Kristiansen, P Deriziotis, DE Dimcheff, GS Jackson, H Ovaa, ...
Molecular cell 26 (2), 175-188, 2007
|Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population|
J Beck, M Poulter, D Hensman, JD Rohrer, CJ Mahoney, G Adamson, ...
The American Journal of Human Genetics 92 (3), 345-353, 2013
MJU Novak, SJ Tabrizi
Bmj 340, 2010
|Mitochondria in the etiology and pathogenesis of Parkinson's disease|
AHV Schapira, M Gu, JW Taanman, SJ Tabrizi, T Seaton, M Cleeter, ...
Annals of neurology 44 (S1 1), S89-S98, 1998
|CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion|
JM Lee, EM Ramos, JH Lee, T Gillis, JS Mysore, MR Hayden, SC Warby, ...
Neurology 78 (10), 690-695, 2012
|Reviewing evidence on complex social interventions: appraising implementation in systematic reviews of the health effects of organisational-level workplace interventions|
M Egan, C Bambra, M Petticrew, M Whitehead
Journal of Epidemiology & Community Health 63 (1), 4-11, 2009